Australians will be offered respiratory vaccines from next year without the usual assessment that ensures they are the most effective available at the best possible price, under the confidential $2bn onshore manufacturing deal the Morrison government struck with Moderna.
The agreement exempts Moderna’s mRNA vaccines from assessment by the Pharmaceutical Benefits Advisory Committee, a government memorandum has revealed.
